ENCRT-103-hPI: Evaluation of an Immune-protected ENCRT-103-hPI Containing Primary Human Islets in Adults With Type 1 Diabetes, With and Without Standard-of-care Portal Vein Islet Infusion.

NCT07680673 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 1 Diabetes

Interventions

DEVICE: ENCRT-103-hPI encompasses the ENC-103 device, which will be implanted once loaded with primary islet cargo.

Sponsor

Encellin